One‑year graft failure‑free survival reaches 90% in crossmatch‑positive transplants
News
Hutchmed reports phase 3 SANOVO data for first‑line lung cancer
Combination shows strong PFS and OS gains in MET‑overexpressing EGFRm disease
Radiotherapy boosts progression‑free survival in advanced lung cancer
SARON trial shows 56% improvement over standard treatment
Mad for it
MAD World Summit 2026 has secured official accreditation from The CPD Group
Microbiotica presents phase 1b data for MB097 at ESMO 2026
Early responses suggest restored sensitivity to anti‑PD‑1 therapy
FDA approves Hibsago for chronic hepatitis B
First-in-class therapy offers functional cure potential
FDA approves Enspryng for at‑home TED treatment
First SC option offers new flexibility for patients
EU approves teclistamab monotherapy for earlier myeloma use
Second-line authorisation expands immunotherapy options
Sitryx reports phase 1b data for SYX-5219
Results support advancement into phase 2 trials
ViiV and Axmed expand access to HIV medicines
Agreement enables procurement in over 50 countries
Osivax reports phase 2b data for OVX836
Results support combination strategy for influenza vaccines
Merz completes phase 3 recruitment for XEOMIN
Global trials assess migraine prevention potential
CHMP backs TALVEY plus daratumumab for earlier myeloma use
Recommendation supports second-line combination option
CHMP backs RASONQUE for metastatic pancreatic cancer
Positive opinion supports EU marketing authorisation
Libtayo dosing backed by CHMP
Regimen update recommended across all indications
